Leukocytoclastic Vasculitis Associated with Clarithromycin

Gavura, Scott R; Nusinowitz, Sidney

doi:10.1345/aph.17286

Cited by 33 publications

(13 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…12,31,34 The lack of significant histopathologic superficial mucosal changes and the fact that only the muscular and serosal venules were primarily involved by LCV are noteworthy in our case. It suggests that the vasculitis might have resulted from a sensitizing factor originating systemically and not from the colonic lumen; as a result, LCV vessel involvement was the cause, not colon dilation.…”

Section: Gastrointestinal (Gi) Involvement In Patients Withmentioning

confidence: 60%

“…5,11,12,14,22,[24][25][26][27][28][29][30][31] Radiologic evidence of bowel wall thickening and mesenteric edema and the endoscopic abnormalities of erosive gastritis and hyperemic duodenitis associated with this condition have been described. [27][28][29]32 Focusing on the more unusual colonic involvement of adult-type LCV associated with HSP, a MEDLINE search revealed 11 bibliographic references in which the colon is reported to be involved by the vasculitic process: specifically, four patients with massive colo- rectal bleeding, 10,13 two with acute abdomen caused by right colon necrosis, 33 one with large bowel perforation, 25 two with punctuate erythematous lesions in the colon plus occult heme-positive stool, 2 one case of associated clarithromycin use, 34 and seven patients with endoscopic findings of mucosal petechiae and submucosal bleeding. 31,[35][36][37][38] In addition, LCV not associated with HSP leading to overt clinical signs of bowel involvement is reported in two cases.…”

Section: Gastrointestinal (Gi) Involvement In Patients Withmentioning

confidence: 99%

See 1 more Smart Citation

Isolated Colonic Leukocytoclastic Vasculitis Causing Segmental Megacolon: Report of a Rare Case

Vlahos¹,

Theodoropoulos²,

Lazaris

et al. 2005

Diseases of the Colon &Amp; Rectum

View full text Add to dashboard Cite

We report the case of a 44-year-old white man who presented with progressively worsening crampy abdominal pain and distention. Deterioration of his clinical picture along with leukocytosis and radiographic evidence of severe colonic dilation rendered exploratory laparotomy necessary. Greatly distended and inflamed transverse and descending colon were evident and an extended left colectomy was performed. Characteristic changes of leukocytoclastic vasculitis in the serosal and muscular layers of the resected colon were demonstrated at histopathologic examination. Systemic leukocytoclastic vasculitis, usually coexisting with Henoch-Schonlein purpura, commonly affects the small bowel with clinical evidence of ischemia or bleeding. Colon involvement is infrequently reported in the context of systemic disease. Isolated colonic leukocytoclastic vasculitis without extraintestinal manifestations is rare. A previously unreported case of localized leukocytoclastic vasculitis of the left colon resulting in the impressive presentation of megacolon, without the presence of any precipitating factor or associated systemic disease is presented here, with an overview of the related literature.

show abstract

Section: Gastrointestinal (Gi) Involvement In Patients Withmentioning

confidence: 60%

Section: Gastrointestinal (Gi) Involvement In Patients Withmentioning

confidence: 99%

Isolated Colonic Leukocytoclastic Vasculitis Causing Segmental Megacolon: Report of a Rare Case

Vlahos¹,

Theodoropoulos²,

Lazaris

et al. 2005

Diseases of the Colon &Amp; Rectum

View full text Add to dashboard Cite

show abstract

“…The most common adverse effects of clarithromycin have been nausea and vomiting. Only a few cases of adverse cutaneous reactions, including thrombocytopenic purpura, 4 leukocytoclastic vasculitis 5,6 and fixed drug eruption have been reported 7 . Here we report a rare case of clarithromycin‐induced fixed drug eruption with a negative patch test result, but positive peroral provocation testing.…”

Section: Reportmentioning

confidence: 81%

Fixed drug eruption due to clarithromycin

Hamamoto

Ohmura

Kinoshita

et al. 2001

Clinical and Experimental Dermatology

View full text Add to dashboard Cite

Clarithromycin is one of the macrolide antibiotics used for cutaneous and respiratory system infections. Only a few cases of adverse cutaneous reactions to this drug have been reported. Here we report a rare case of clarithromycin-induced fixed drug eruption which could be reproduced by a peroral provocation test, whereas patch tests on both unaffected and residual pigmented skin yielded negative results. All cutaneous lesions that recurred due to the challenge test developed the same pigmentation after a short course of intravenous corticosteroid.

show abstract

“…Developing a new pharmaceutical is time consuming and expensive: development times are often longer than a decade, and the cost can range from $US800 million to $US1.2 billion. 1 Consequently, the National Institutes of Health (NIH) announced a new funding program in 2012 for the repurposing of 58 approved drugs. 2 Recombinant erythropoietin (EPO) is an attractive candidate for repurposing and developing as an agent to treat acute or chronic skin wounds.…”

mentioning

confidence: 99%

Erythropoietin, a novel repurposed drug: An innovative treatment for wound healing in patients with diabetes mellitus

Hamed

Bennett

Demiot

et al. 2013

Wound Repair Regeneration

View full text Add to dashboard Cite

Developing a new drug is expensive: the cost of going from bench to bedside is about $US1 billion. Therefore, the repurposing of an approved drug is potentially rewarding because it expands the drug's existing therapeutic profile and preempts additional development costs. As the safety profile of a repurposed drug is already well known, any new investigations could then focus on its efficacy and other therapeutic benefits. Recombinant erythropoietin (EPO) is a potential candidate for repurposing because the results of numerous studies have shown that systemic and topical EPO is therapeutically beneficial when it is administered to healthy and diabetic animals with acute and chronic skin wounds and burns. Moreover, the molecular mechanisms of EPO's actions have been elucidated: EPO acts on those nonhematopoietic cells which are involved in the innate immune response where it promotes cellular proliferation and differentiation, exerts its cytoprotective actions, and inhibits apoptosis. In this review, the mechanism of EPO's action in skin wound healing is reviewed, and its potential for treating acute and chronic skin wounds and stimulating tissue regeneration in diabetic patients is discussed.

show abstract

Leukocytoclastic Vasculitis Associated with Clarithromycin

Abstract: Leukocytoclastic vasculitis induced by clarithromycin is a rare but serious potential adverse effect.

Cited by 33 publications

References 7 publications

Isolated Colonic Leukocytoclastic Vasculitis Causing Segmental Megacolon: Report of a Rare Case

Isolated Colonic Leukocytoclastic Vasculitis Causing Segmental Megacolon: Report of a Rare Case

Fixed drug eruption due to clarithromycin

Erythropoietin, a novel repurposed drug: An innovative treatment for wound healing in patients with diabetes mellitus

Contact Info

Product

Resources

About